TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01095679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Description: Breaking tablets of 10 mg of baclofen. Dosage and frequency : 5 mg 3 times a day for 3 days, then 10 mg 3 times a day for 3 days, then 15 mg 3 times a day for 3 days, then 20 mg 3 times a day for 3-5 days, then 15 mg 3 times a day for 1 day, then 10 mg 3 times a day for one day, then 5 mg 3 times a day for one day.
Study: NCT03160625

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rate Adaptive Pacing
Description: Rate Adaptive Pacing varies the pacing rate in response to the patient's physical motion as detected by an activity sensor.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rate Adaptive Pacing
Description: Rate Adaptive Pacing varies the pacing rate in response to the patient's physical motion as detected by an activity sensor.
Study: NCT04607629

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Genolar® + Symbicort®
Description: The experimental drug dose and administration frequency were determined based on baseline IgE concentration (IU / ml) measured before treatment and current body weight (kg). Depending on the initial IgE concentration and body weight the recommended drug dose was from 75 to 600 mg once in 2 or 4 weeks. The experimental drug Genolar® and the reference drug Xolair® were administered subcutaneously for 26 weeks. Budesonide + formoterol inhalation (dosed powder for inhalation, each delivered dose contains 320 μg budesonide and formoterol fumarate dihydrate 9 μg)) 1 inhalation 2 times a day.
Study: NCT01095679

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Breaking tablets of 10 mg of placebo. Dosage and frequency : 5 mg 3 times a day for 3 days, then 10 mg 3 times a day for 3 days, then 15 mg 3 times a day for 3 days, then 20 mg 3 times a day for 3-5 days, then 15 mg 3 times a day for 1 day, then 10 mg 3 times a day for one day, then 5 mg 3 times a day for one day.
Study: NCT01405131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: constituted powder for oral suspension 4 mg/mL single dose at 32 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: tablets 32 mg single dose
Study: NCT01374139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: 5 clinical 100 mg tablets and 100 mg capsules, 500 mg, single dose, 2x2 crossover under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: 4 commercial 100 mg tablets, 400 mg, single dose, 2x2 crossover under fed/fast condition
Study: NCT04607629

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Xolair® + Symbicort®
Description: The experimental drug dose and administration frequency were determined based on baseline IgE concentration (IU / ml) measured before treatment and current body weight (kg). Depending on the initial IgE concentration and body weight the recommended drug dose was from 75 to 600 mg once in 2 or 4 weeks. The experimental drug Genolar® and the reference drug Xolair® were administered subcutaneously for 26 weeks. Budesonide + formoterol inhalation (dosed powder for inhalation, each delivered dose contains 320 μg budesonide and formoterol fumarate dihydrate 9 μg)) 1 inhalation 2 times a day.
Study: NCT01800786

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Study: NCT04232241

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic Stem Cell Transplantation
Description: Allogeneic Stem Cell Transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic Stem Cell Transplantation
Description: Allogeneic Stem Cell Transplantation
Study: NCT02206074

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot
Study: NCT00773942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic medication therapy management
Description: Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview alone.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced medication therapy management
Description: Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview and chart information.
Study: NCT02932228

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ImPACT
Description: The ImPACT team offers the following services:~* An intensive intake process, including a home visit if deemed appropriate~* Frequent contact (in-person, telephone, or secure messaging) tailored to a patient's needs~* After-hours access to on-call team member in order to avoid unnecessary emergency care~* Optimization of chronic condition management using evidence-based protocols~* Navigation of transitions between hospital and home~* Coordination of specialty care, including contact with specialists when indicated~* Rapid response to signs of health status deterioration or other stressful events~* Assess patient goals, advance directives, Physician Orders for Life-Sustaining Treatment
Study: NCT01890070

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chestnut
Description: Italian Organic Chestnut
Study: NCT01072266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB028060
Description: 10 mg and 50 mg capsules will be provided and dosed per the dosing schedule.
Study: NCT02469779

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Surveys
Description: At baseline participants complete survey about their mental and physical health and their opinions concerning health information and the internet. The survey will take about 15-20 minutes to complete.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Surveys
Description: At baseline participants complete survey about their mental and physical health and their opinions concerning health information and the internet. The survey will take about 15-20 minutes to complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASPIRE Website
Description: Participants view the ASPIRE website containing videos, activities, and health information facts about the effects of smoking, the benefits of meditation, and healthy living. This viewing will be videotaped

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ASPIRE Text-Based Website
Description: Participants view the ASPIRE text-based website containing health information facts about smoking, the benefits of meditation, and healthy living.
Study: NCT01332643

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Preimplantation Genetic Diagnosis
Description: All embryos in the test group reaching blastocyst stage will undergo embryo biopsy of 3-10 trophectoderm cells. The cells will be analyzed by array CGH to detect the presence or not of chromosome abnormalities. The embryos will be vitrified and those classified by array CGH as normal, thawed for replacement.
Study: NCT03988088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally.
Study: NCT02109211

Intervention type: DEVICE
Group type: OTHER
Intervention: Intubation with Magill forceps

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubation with altered Magill forceps
Study: NCT03638609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra Aortic Balloon Pump
Description: Intra Aortic Balloon Pump (IABP) is a circulatory mechanical support device, placed in descending aorta, distally from left subclavian artery and proximally from renal artery. IABP works with counterpulsation concept, synchronized with heart cycle. It is indicated as supportive therapy for patients undergoing revascularization, cardiogenic shock and mechanical complication.~Balloon dilatation during dyastolic phase increasing dyastolic pressure in aorta, improving coronary vascularization and myocardial oxygen supply. In systolic phase, the balloon deflates, reducing the left ventricle afterload hence decreasing myocardial oxygen demand.
Study: NCT00532558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate
Description: Lapaquistat acetate 50 mg, tablets, orally, once daily for up to 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily for up to 12 weeks.
Study: NCT02469779

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow Up Survey
Description: Participants complete a follow-up survey about their opinions concerning health information and the internet immediately after they have completed their last session on the website.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow Up Survey
Description: Participants complete a follow-up survey about their opinions concerning health information and the internet immediately after they have completed their last session on the website.
Study: NCT03231319

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascia iliaca compartment block with IV-PCA
Description: 1. Fascia iliaca compartment block: The injection was performed under ultrasound guidance. Surface landmark is identified on the line between anterior superior iliac spine and pubic tubercle. The injection site is at the medial one-third of the line. The needle is threaded medial to lateral and standardization of local anesthetic deposit is in the fascia plane between fascia iliaca and iliacus muscle. Anesthetic regimen: 2% xylocaine 15mL + 0.5% bupivacaine 15mL.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral nerve block and lateral femoral cutaneous nerve with IV-PCA
Description: 1. Femoral nerve block: The injection was performed under ultrasound guidance. Femoral nerve was identified in the femoral neurovascular bundle below or around inguinal ligament. The needle is threaded with lateral to medial approach. Local anesthetics will be deposited around the femoral nerve, the standardization of protocol is that femoral nerve should be lifted off from iliacus muscle. Anesthetic regimen: 2% xylocaine 10mL + 0.5% bupivacaine 10mL.~2. Lateral femoral cutaneous nerve block: The injection was performed under ultrasound guidance. Lateral femoral cutaneous nerve was identified in the fascia plane between sartorius muscle and tensor fascia lata muscle. Anesthetic regimen: 2% xylocaine 5mL + 0.5% bupivacaine 5mL
Study: NCT03493607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMO-01
Description: Subjects will receive a single 6-hour intravenous infusion for a total dose administration or 120 mg/m2 of AMO-01.
Study: NCT03513458

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: A single 1mg/kg subcutaneous injection (up to 100 mg) of Anakinra will be administered at the onset of the LPR, roughly three hours post allergen challenge, to model Anakinra use in an emergency care setting.
Study: NCT03231319

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: IV-PCA
Description: IV-PCA was programmed and provided to the patient for optimize pain control
Study: NCT04487743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients were randomly assigned, in a 2:1 ratio, to receive once-daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg, or placebo; both groups received counseling on lifestyle modification

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients were randomly assigned, in a 2:1 ratio, to receive once-daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg, or placebo; both groups received counseling on lifestyle modification
Study: NCT01904006

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: New Culture Condition
Description: Intervention group embryos cultured grouped (5 embryos per drop) under low oxygen tension (5%) in benchtop incubators.
Study: NCT03513458

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: A single 1mg/kg subcutaneous injection (up to 100 mg) of Anakinra will be administered at the onset of the LPR, roughly three hours post allergen challenge, to model Anakinra use in an emergency care setting.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anakinra Matching Placebo
Description: A single dose of matching placebo will be administered at the onset of the LPR, roughly three hours post allergen challenge, to model Anakinra use in an emergency care setting.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anakinra Matching Placebo
Description: A single dose of matching placebo will be administered at the onset of the LPR, roughly three hours post allergen challenge, to model Anakinra use in an emergency care setting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermatophagoides Farinae
Description: Standardized house dust mite Dermatophagoides farinae (D. farinae) allergen extract at 30,000 allergen units (AU)/mL for inhalation (provided by Greer Laboratories, Lenoir, NC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermatophagoides Farinae
Description: Standardized house dust mite Dermatophagoides farinae (D. farinae) allergen extract at 30,000 allergen units (AU)/mL for inhalation (provided by Greer Laboratories, Lenoir, NC).
Study: NCT01904006

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Culture Condition
Description: Control group embryos cultured individually (1 embryo per drop) under atmospheric oxygen tension (20%) in large-box incubators.
Study: NCT04056975

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Anti-CD19m-CD3 Antibody Injection
Description: Intravenous Infusion
Study: NCT02972177

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: Transbronchial radiofrequency ablation will be performed under the guidance of navigation bronchoscopy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave ablation
Description: Transbronchial microwave ablation will be performed under the guidance of navigation bronchoscopy.
Study: NCT03629600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactated Ringer
Description: High-volume Lactated Ringer Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rectal Form Indometacin
Description: Post-ERCP rectal administration of 100 MG Indomethacin
Study: NCT04032158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Description: Participants received evobrutinib twice daily (BID).
Study: NCT02812745

Intervention type: DEVICE
Intervention: recording of cardiac output

Intervention type: DEVICE
Intervention: other parameters
Description: BIS (bispectral index ), PI (perfusion index ), etCO2 (end-tidal carbon dioxide ), and brain NIRS (near-infrared spectroscopy)
Study: NCT03313973

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: with self stretching same muscle
Description: with self stretching

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: with self stretching of forearm muscles
Description: without self stretching
Study: NCT03891888

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intramedullary Bone Graft
Description: Patients in this group will undergo standard treatment for their open tibia shaft fracture (irrigation and debridement of their open fracture and reamed intramedullary nailing), but will also have the reamings from the medullary canal preparation collected and packed into the exposed fracture cortex
Study: NCT03780257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QR-421a
Description: RNA antisense oligonucleotide for intravitreal injection

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham-procedure (dose cohort 1&2 only)
Description: Sham-procedure (no experimental drug administered)
Study: NCT00685061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Induction
Study: NCT01890070

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Dietary Supplement
Description: Mediterranean Reference Diet, High Fat Diet, Low Carbohydrate or High Protein Diet without an added dietary supplement (hazelnut, chocolate, red wine, wild mixed greens, chestnuts, olive oil)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Dietary Supplement
Description: Mediterranean Reference Diet, High Fat Diet, Low Carbohydrate or High Protein Diet without an added dietary supplement (hazelnut, chocolate, red wine, wild mixed greens, chestnuts, olive oil)
Study: NCT01234441

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Control
Description: A placebo non-nutritive beverage will be administered before dialysis sessions 3 times per week.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein
Description: A whey protein beverage will be administered before dialysis sessions 3 times per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Protein + Exercise
Description: A whey protein beverage will be administered before dialysis sessions 3 times per week. Patients will also exercise by stationary bicycle during dialysis sessions 3 times per week.
Study: NCT03658239

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inversion
Description: Inversions will be done while the subject is on the inversion table. The subject will be inverted to 135, 150 and 165 degrees. There inversion will not last longer than 3 minutes at a time. The inversion will be terminated if the subject's blood pressure drops below 50 mmHg diastolic or if the subject's blood pressure increases more than 50 mmHg systolic.
Study: NCT02221687

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic formula
Description: Standard milk formula enriched with a prebiotic fiber and a probiotic strain

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control formula
Description: Standard milk formula without pre and probiotic
Study: NCT05675176

Intervention type: DRUG
Intervention: BCG
Description: Intravesical Instillation

Intervention type: DRUG
Intervention: BCG
Description: Intravesical Instillation
Study: NCT03087643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive mobilization - PM
Study: NCT05161767

Intervention type: DIAGNOSTIC_TEST
Intervention: Brain MRI (neuroimaging)
Description: Structural and functional brain scans will be taken.

Intervention type: DIAGNOSTIC_TEST
Intervention: Brain MRI (neuroimaging)
Description: Structural and functional brain scans will be taken.
Study: NCT01193595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ombrabulin (AVE8062)
Description: Pharmaceutical form:Solution for infusion~Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Pharmaceutical form:Solution for infusion~Route of administration: Intravenous
Study: NCT03622073

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Misoprostol treatment by Midwife
Description: Medical management of incomplete abortion
Study: NCT02359188

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous vagal nerve stimulation
Description: 4 hours of transcutaneous vagal nerve stimulation
Study: NCT00439569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium phenylbutyrate
Description: 500 mg/kg/day, depending upon tolerability subsequent dosages may increase to 675, 900, or 1200 mg/kg/day to identify maximum tolerated dose (MTD) and then an additional 6 participants will enroll at the MTD
Study: NCT02364349

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bee Venom (BV)
Description: Raw Bee Venom
Study: NCT03170479

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Two doses of Vitamin D supplementation in ampoules form (ED3) were procured. Ampoule contains Cholecalciferol in 200,000 IU both for oral and intra muscular use.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ready to Use Therapeutic Food (RUTF)
Description: RUTF is recommended by WHO for sever malnourished children in community settings as a therapeutic diet. The quantity depends upon the child body weight.
Study: NCT02364349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Essential Bee Venom (e-BV)
Description: Bee venom without Hyaluronidase, Lysophospholipase, α-D-glucosidase, PLA2, Adolapin
Study: NCT03170479

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready to Use Therapeutic Food (RUTF)
Description: RUTF is recommended by WHO for sever malnourished children in community settings as a therapeutic diet. The quantity depends upon the child body weight.
Study: NCT03714282

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive spinal stimulation with gait training
Description: Transcutaneous Spinal Cord Neurostimulator will deliver transcutaneous electrical spinal cord stimulation while subjects perform locomotor activities.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional gait training
Description: May receive up to 50 min of locomotion training without transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.

Intervention type: OTHER
Group type: OTHER
Intervention: Healthy control group
Description: Participant in the Healthy Control Group will participate in up to 3 assessment sessions in order to obtain comparative data for Spinal Motor Evoked Potentials (MEPs), lower extremity MVC's, sidelying EMG data and overground EMG data